ExpansionJun 1, 2026, 07:02 AM
Kamada Gets FDA Approval for New RFFIT Lab in Israel
AI Summary
Kamada Ltd. announced FDA approval for its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory, located at its Beit Kama, Israel plant. This state-of-the-art facility, also approved by Health Canada and the Israeli Ministry of Health, significantly expands the company's advanced testing capabilities for Anti-Rabies potency in the manufacturing of KEDRAB® and KAMRAB®. The new lab is expected to drive increased operational efficiencies and reinforces Kamada's commitment to innovation and quality, supporting products that generated over $70 million in sales in 2025.
Key Highlights
- Kamada received FDA approval for its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory.
- The RFFIT lab is located in Kamada's plant in Beit Kama, Israel.
- The lab was also approved by Health Canada and the Israeli Ministry of Health.
- It expands advanced testing capabilities for Anti-Rabies potency in KEDRAB® and KAMRAB® manufacturing.
- KEDRAB and KAMRAB sales exceeded $70 million in 2025, representing a leading franchise.
- The new lab is expected to increase operational efficiencies and enhance quality infrastructure.
Price Impact
More from KMDA